Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings

Published:2020-03-31 Issue:7 Volume:147 Page:1970-1978
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Tak Kwon Yong¹,Nam Hee Chul¹,Choi Jong Young¹,Yoon Seung Kew¹,Kim Chang Wook²,Kim Hee Yeon²,Lee Sung Won³^ORCID,Lee Hae Lim³,Chang U Im⁴,Song Do Seon⁴,Yang Jin Mo⁵,Kwon Jung Hyun⁵^ORCID,Yoo Sun Hong⁵,Sung Pil Soo¹^ORCID,Choi Sang Wook⁶,Song Myeong Jun⁷,Kim Seok Hwan⁷,Jang Jeong Won¹^ORCID

Affiliation:

1. Department of Internal MedicineSeoul St. Mary's Hospital, College of Medicine Seoul South Korea

2. Uijeongbu St. Mary's Hospital Seoul South Korea

3. Bucheon St. Mary's Hospital Seoul South Korea

4. St. Vincent's Hospital Seoul South Korea

5. Incheon St. Mary's Hospital Seoul South Korea

6. St. Paul's Hospital Seoul South Korea

7. Daejeon St. Mary's Hospital Seoul South Korea

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32964

Reference24 articles.

1. Cancer statistics, 2020

2. AASLD guidelines for the treatment of hepatocellular carcinoma

3. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies

4. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

5. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment;Journal of Hepatology;2024-08

2. Fasting in combination with the cocktail Sorafenib:Metformin blunts cellular plasticity and promotes liver cancer cell death via poly-metabolic exhaustion;Cellular Oncology;2024-07-11

3. The effects of low-dose sorafenib on epithelial-mesenchymal transition and multidrug resistance markers in HepG2 cell line;The European Research Journal;2023-03-04

4. Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study;Journal of the American Heart Association;2023-01-03

5. Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study;Anticancer Research;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3